You are here

  • Home
  • Archive
  • Volume 12, Issue 4
  • Combining CRISPR-Cas9 and TCR exchange to generate a safe and efficient cord blood-derived T cell product for pediatric relapsed AML

Article metrics

Article menu
Immune cell therapies and immune cell engineering
Original research
Combining CRISPR-Cas9 and TCR exchange to generate a safe and efficient cord blood-derived T cell product for pediatric relapsed AML

 

Online download statistics by month:

Online download statistics by month: April 2024 to February 2026

AbstractFullPdf
Apr 2024641653280
May 202413113584
Jun 202412812963
Jul 202410110577
Aug 2024909472
Sep 2024969661
Oct 202410610652
Nov 202410210356
Dec 202417718479
Jan 202514014048
Feb 202531031175
Mar 202512312467
Apr 202514614658
May 202510410562
Jun 2025717232
Jul 2025110
Sep 2025110
Feb 2026210
Total247025061166